Literature DB >> 26833193

Oxidative stress does not play a primary role in the toxicity induced with clinical doses of doxorubicin in myocardial H9c2 cells.

Tareck Rharass1,2, Adam Gbankoto3, Christophe Canal1, Gizem Kurşunluoğlu4, Amandine Bijoux1, Daniela Panáková2, Anne-Cécile Ribou5,6.   

Abstract

The implication of oxidative stress as primary mechanism inducing doxorubicin (DOX) cardiotoxicity is still questionable as many in vitro studies implied supra-clinical drug doses or unreliable methodologies for reactive oxygen species (ROS) detection. The aim of this study was to clarify whether oxidative stress is involved in compliance with the conditions of clinical use of DOX, and using reliable tools for ROS detection. We examined the cytotoxic mechanisms of 2 μM DOX 1 day after the beginning of the treatment in differentiated H9c2 rat embryonic cardiac cells. Cells were exposed for 2 or 24 h with DOX to mimic a single chronic dosage or to favor accumulation, respectively. We found that apoptosis was prevalent in cells exposed for a short period with DOX: cells showed typical hallmarks as loss of anchorage ability, mitochondrial hyperpolarization followed by the collapse of mitochondrial activity, and nuclear condensation. Increasing the exposure period favored a shift to necrosis as the cells preferentially exhibited early DNA impairment and nuclear swelling. In either case, measuring the fluorescence lifetime of 1-pyrenebutyric acid or the intensities of dihydroethidium or amplex red showed a consistent pattern in ROS production which was a slight increased level far from representative of an oxidative stress. Moreover, pre-treatment with dexrazoxane provided a cytoprotective effect although it failed to detoxify ROS. Our data support that oxidative stress is unlikely to be the primary mechanism of DOX cardiac toxicity in vitro.

Entities:  

Keywords:  Apoptosis; Cardiotoxicity; Dexrazoxane; Doxorubicin; Necrosis; Oxidative stress

Mesh:

Substances:

Year:  2016        PMID: 26833193     DOI: 10.1007/s11010-016-2653-x

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  67 in total

1.  The apoptosis-necrosis paradox. Apoptogenic proteases activated after mitochondrial permeability transition determine the mode of cell death.

Authors:  T Hirsch; P Marchetti; S A Susin; B Dallaporta; N Zamzami; I Marzo; M Geuskens; G Kroemer
Journal:  Oncogene       Date:  1997-09-25       Impact factor: 9.867

2.  Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro.

Authors:  Paolo Spallarossa; Silvano Garibaldi; Paola Altieri; Patrizia Fabbi; Valeria Manca; Sabina Nasti; Pierfranco Rossettin; Giorgio Ghigliotti; Alberto Ballestrero; Franco Patrone; Antonio Barsotti; Claudio Brunelli
Journal:  J Mol Cell Cardiol       Date:  2004-10       Impact factor: 5.000

3.  Tanshinone IIA protects neonatal rat cardiomyocytes from adriamycin-induced apoptosis.

Authors:  Jie Gao; Guoqing Yang; Rongbiao Pi; Ruifang Li; Ping Wang; Huijie Zhang; Kang Le; Shaorui Chen; Peiqing Liu
Journal:  Transl Res       Date:  2007-12-28       Impact factor: 7.012

4.  Scavenging effects of dexrazoxane on free radicals.

Authors:  Zhang Junjing; Zhao Yan; Zhao Baolu
Journal:  J Clin Biochem Nutr       Date:  2010-10-29       Impact factor: 3.114

5.  NADPH oxidases participate to doxorubicin-induced cardiac myocyte apoptosis.

Authors:  Mylène Gilleron; Xavier Marechal; David Montaigne; Jessica Franczak; Remi Neviere; Steve Lancel
Journal:  Biochem Biophys Res Commun       Date:  2009-08-20       Impact factor: 3.575

6.  Metabolism of dexrazoxane (ICRF-187) used as a rescue agent in cancer patients treated with high-dose etoposide.

Authors:  Patricia E Schroeder; Peter Buhl Jensen; Maxwell Sehested; Kenneth Francis Hofland; Seppo W Langer; Brian B Hasinoff
Journal:  Cancer Chemother Pharmacol       Date:  2003-05-15       Impact factor: 3.333

Review 7.  Apoptosis, oncosis, and necrosis. An overview of cell death.

Authors:  G Majno; I Joris
Journal:  Am J Pathol       Date:  1995-01       Impact factor: 4.307

8.  The metabolites of the cardioprotective drug dexrazoxane do not protect myocytes from doxorubicin-induced cytotoxicity.

Authors:  Brian B Hasinoff; Patricia E Schroeder; Daywin Patel
Journal:  Mol Pharmacol       Date:  2003-09       Impact factor: 4.436

9.  Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy.

Authors:  Elke Martin; Annemette Vinding Thougaard; Morten Grauslund; Peter B Jensen; Fredrik Bjorkling; Brian B Hasinoff; Jette Tjørnelund; Maxwell Sehested; Lars H Jensen
Journal:  Toxicology       Date:  2008-10-25       Impact factor: 4.221

10.  Reduction in mitochondrial potential constitutes an early irreversible step of programmed lymphocyte death in vivo.

Authors:  N Zamzami; P Marchetti; M Castedo; C Zanin; J L Vayssière; P X Petit; G Kroemer
Journal:  J Exp Med       Date:  1995-05-01       Impact factor: 14.307

View more
  8 in total

1.  Embryonic stem cell-derived exosomes inhibit doxorubicin-induced TLR4-NLRP3-mediated cell death-pyroptosis.

Authors:  Zahra Tavakoli Dargani; Dinender K Singla
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-06-07       Impact factor: 4.733

2.  A Personalized Model of COQ2 Nephropathy Rescued by the Wild-Type COQ2 Allele or Dietary Coenzyme Q10 Supplementation.

Authors:  Jun-Yi Zhu; Yulong Fu; Adam Richman; Zhanzheng Zhao; Patricio E Ray; Zhe Han
Journal:  J Am Soc Nephrol       Date:  2017-04-20       Impact factor: 10.121

3.  The Prophylactic Effect of Pinocembrin Against Doxorubicin-Induced Cardiotoxicity in an In Vitro H9c2 Cell Model.

Authors:  Nonhlakanipho F Sangweni; Malebogo Moremane; Sylvia Riedel; Derick van Vuuren; Barbara Huisamen; Lawrence Mabasa; Reenen Barry; Rabia Johnson
Journal:  Front Pharmacol       Date:  2020-08-05       Impact factor: 5.810

Review 4.  Personalized medicine in cardio-oncology: the role of induced pluripotent stem cell.

Authors:  Nazish Sayed; Mohamed Ameen; Joseph C Wu
Journal:  Cardiovasc Res       Date:  2019-04-15       Impact factor: 10.787

Review 5.  Statins in anthracycline-induced cardiotoxicity: Rac and Rho, and the heartbreakers.

Authors:  Christian Henninger; Gerhard Fritz
Journal:  Cell Death Dis       Date:  2017-01-19       Impact factor: 8.469

6.  Doxorubicin induces cardiotoxicity through upregulation of death receptors mediated apoptosis in cardiomyocytes.

Authors:  Liqun Zhao; Baolin Zhang
Journal:  Sci Rep       Date:  2017-03-16       Impact factor: 4.379

7.  Metabolic Conversion and Removal of Manganese Ferrite Nanoparticles in RAW264.7 Cells and Induced Alteration of Metal Transporter Gene Expression.

Authors:  Liang Zhang; Shilin Xiao; Xun Kang; Tao Sun; Chunyu Zhou; Zhongsheng Xu; Mengmeng Du; Ya Zhang; Guangxian Wang; Yun Liu; Dong Zhang; Mingfu Gong
Journal:  Int J Nanomedicine       Date:  2021-03-01

Review 8.  Cardiotoxicity of Antineoplastic Therapies and Applications of Induced Pluripotent Stem Cell-Derived Cardiomyocytes.

Authors:  Mo-Fan Huang; Lon Kai Pang; Yi-Hung Chen; Ruiying Zhao; Dung-Fang Lee
Journal:  Cells       Date:  2021-10-21       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.